Outlook Therapeutics (OTLK) News Today → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free OTLK Stock Alerts $7.43 +0.03 (+0.41%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 5:00 PM | globenewswire.comOutlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateMay 14 at 2:49 AM | americanbankingnews.comOutlook Therapeutics (OTLK) Set to Announce Quarterly Earnings on ThursdayMay 13 at 8:50 AM | globenewswire.comOutlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDMay 10, 2024 | marketbeat.comOutlook Therapeutics (OTLK) to Release Quarterly Earnings on ThursdayOutlook Therapeutics (NASDAQ:OTLK) will be releasing earnings before the market opens on Thursday, May 16, Zacks reports.May 9, 2024 | finance.yahoo.comOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastMay 9, 2024 | globenewswire.comOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastMay 8, 2024 | americanbankingnews.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 3, 2024 | finance.yahoo.comGlobal $320 Billion Aviation Fuel Market Outlook, 2024-2029: Emission Reduction Initiatives, Rising Air Freight Demand, Emerging MarketsMay 3, 2024 | msn.comHow to fix Microsoft OutlookMay 2, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Retina World Congress 2024April 29, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseApril 29, 2024 | msn.comThese 5 programs are way better than Microsoft OutlookApril 29, 2024 | usnews.comHCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 OutlookApril 29, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation CouncilApril 26, 2024 | finance.yahoo.comGlobal Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036April 26, 2024 | msn.comHow to Use Copilot in OutlookApril 22, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to PositiveApril 22, 2024 | markets.businessinsider.comWGA Releases New Housing Finance OutlookApril 22, 2024 | msn.comOutlook: How to set up breaks between your meetingsApril 21, 2024 | finance.yahoo.comOutlook Therapeutics, Inc. (OTLK)April 18, 2024 | finance.yahoo.comWorld Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and PricesApril 18, 2024 | usnews.comBosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024April 15, 2024 | globenewswire.comOutlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 14, 2024 | msn.comUS Consumer Sentiment Falls Slightly as Outlook for Inflation WorsensApril 14, 2024 | msn.comMicrosoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot?April 11, 2024 | fxstreet.comFed's Williams: Outlook is uncertain, Fed must be data-dependentApril 11, 2024 | msn.comStock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate CutApril 11, 2024 | msn.comBitdefender now has identity protection for Gmail and OutlookApril 10, 2024 | finance.yahoo.comInsiders are Piling into These 10 Healthcare Stocks in 2024April 3, 2024 | forbes.comUsers Complain Gmail Blocks Email From Microsoft Outlook—Here’s The FixApril 3, 2024 | msn.comOutlook.com trips over Google's spam blocking rulesMarch 30, 2024 | insidertrades.comYezan Munther Haddadin Purchases 1,882 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) StockMarch 29, 2024 | uk.investing.comBTIG upgrades Outlook Therapeutics stock to buy, cites ONS-5010 successMarch 29, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Acquires 1,882 SharesOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin acquired 1,882 shares of Outlook Therapeutics stock in a transaction that occurred on Thursday, March 28th. The shares were purchased at an average cost of $11.82 per share, for a total transaction of $22,245.24. Following the purchase, the director now directly owns 5,049 shares of the company's stock, valued at approximately $59,679.18. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.March 27, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Down 93.3% in MarchOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 785,300 shares, a drop of 93.3% from the February 29th total of 11,640,000 shares. Approximately 10.6% of the company's stock are short sold. Based on an average trading volume of 496,200 shares, the days-to-cover ratio is currently 1.6 days.March 27, 2024 | markets.businessinsider.comBuy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price TargetMarch 27, 2024 | msn.comOutlook Therapeutics shares rise after 'buy' rating from BTIGMarch 27, 2024 | marketbeat.comOutlook Therapeutics (NASDAQ:OTLK) Upgraded by BTIG Research to BuyBTIG Research raised Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $50.00 price objective for the company in a report on Wednesday.March 25, 2024 | markets.businessinsider.comOutlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market SuccessMarch 25, 2024 | marketbeat.comHC Wainwright Raises Outlook Therapeutics (NASDAQ:OTLK) Price Target to $30.00HC Wainwright lifted their target price on Outlook Therapeutics from $1.50 to $30.00 and gave the stock a "buy" rating in a research report on Monday.March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Outlook Therapeutics: European Endorsement and Pivotal US Study Progress Signal Strong Market PotentialMarch 24, 2024 | nasdaq.comOutlook Therapeutics Surges On Positive CHMP Opinion For ONS-5010March 22, 2024 | msn.comWhy Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?March 22, 2024 | marketwatch.comOutlook Therapeutics Shares Rise Premarket on CHMP Backing of Wet AMD DrugMarch 22, 2024 | msn.comCanopy Growth, Capricor Therapeutics, GT Biopharma among healthcare moversMarch 22, 2024 | markets.businessinsider.comOutlook Therapeutics Receives Positive CHMP Opinion For ONS-5010 To Treat Wet AMDMarch 22, 2024 | marketbeat.comTrading was temporarily halted for "OTLK" at 09:03 AM with a stated reason of "LULD pause."March 22, 2024 | globenewswire.comOutlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDMarch 21, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Outlook Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:OTLK)Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Analysts at Capital One Financial upped their Q2 2024 earnings estimates for shares of Outlook Therapeutics in a research note issued to investors on Monday, March 18th. Capital One Financial analyst T. Chiang now forecasts that the company Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address This is the best new way to score with AI (Ad)If you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open. Click now for the best way into the newest AI projects OTLK Media Mentions By Week OTLK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼0.600.54▲Average Medical News Sentiment OTLK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼74▲OTLK Articles Average Week Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Gritstone bio News Today bluebird bio News Today Sangamo Therapeutics News Today Passage Bio News Today aTyr Pharma News Today Curis News Today Omega Therapeutics News Today Vigil Neuroscience News Today AlloVir News Today CEL-SCI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsDoes this make you sick?Allegiance GoldTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
